Clinical Observation Of Wenfei Zhixiao Prescription In Treating Acute Exacerbation Of Bronchial Asthma(External Cold And Internal Drink Syndrome) And Its Effect On Serum VCAM-1

Objective: Observation of TCM syndrome scores,lung wheezing scores,lung function(FEV1,FEV1/FVC%),ACT score,serum VCAM-1 before and after treatment of Wenfei Zhixiao prescription in patients with acute exacerbation of bronchial asthma(external cold and internal drink syndrome)Changes in the level of the drug were used to evaluate its clinical efficacy and safety.Methods: Sixty-four patients with acute exacerbation of bronchial asthma(mild or moderate)and TCM evidence of external cold and internal drinking were collected in the outpatient clinic of the Department of Respiratory Medicine of the First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine from December 2021 to December 2022.They were divided into treatment group and control group by random single-blind method.During the study,1 case in the treatment group voluntarily withdrew,1case in the control group withdrew due to disease aggravation,and 1 case was lost to follow-up.In the end,31 cases were in the treatment group and 30 cases in the control group.The control group was treated with Seretide(50 ug /250 ug×60 inhalation/bottle)1 inhalation each time,twice a day;on the basis of this,the treatment group was given a daily dose of Wenfei Zhixiao prescription,decocted in 300 ml of water,Take it warm twice in the morning and evening.The total course of treatment is 10 days.The changes of TCM syndrome scores,lung wheezing scores,lung function(FEV1,FEV1/FVC%),ACT scores,serum VCAM-1 levels and safety indicators were observed before and after treatment in the two groups.Results:1.After treatment,the total score of symptoms and individual scores of shortness of breath,cough,sputum,phlegm in the throat,aversion to cold,sore limbs,nasal congestion,sneezing,and chest tightness in the two groups decreased(P<0.05),and the treatment group was better than the control group group(P<0.05).2.After treatment,the scores of wheeze in both groups were lower than before(P<0.05),and the treatment group was better than the control group(P<0.05).3.The lung function(FEV1,FEV1/FVC%)of the two groups improved after treatment(P<0.05),but there was no statistical difference between the two groups(P>0.05).4.The total effective rate of the treatment group was 90.32%,and that of the control group was 83.33%.The curative effect of the treatment group was better than that of the control group(P<0.05).5.After treatment,the ACT scores of both groups were higher than before(P<0.05),and the treatment group was better than the control group(P<0.05).6.After treatment,the serum VCAM-1 levels of the two groups decreased in different degrees(P<0.05),and the treatment group was better than the control group(P<0.05).7.There was no abnormal change in the safety indicators of the two groups before and after treatment,and the safety was good.Conclusions:1.Wenfei Zhixiao prescription can relieve the symptoms of patients with bronchial asthma in the acute attack stage(external cold and internal drink syndrome).2.Wenfei Zhixiao prescription can improve the wheezing sound and lung function of patients with bronchial asthma in the acute attack stage(external cold and internal drink syndrome).3.Wenfei Zhixiao prescription can improve the ACT score of patients with bronchial asthma in the acute attack stage(external cold and internal drink syndrome).4.Wenfei Zhixiao prescription can reduce the serum VCAM-1 level in patients with bronchial asthma in the acute attack stage(external cold and internal drink syndrome).5.Wenfei Zhixiao prescription is safe and effective in treating acute bronchial asthma(external cold and internal drink syndrome).